N/A N=40 Randomized Treatment

Study of Induction Therapy With Mitoxantrone and Plasmapheresis to Treat Aggressive Multiple Sclerosis

Multiple Sclerosis

Bottom Line

View on ClinicalTrials.gov: NCT01214317 ↗

Enrolled (actual)

Serious AEs

0.0%

Results posted

Sep 2020

Primary outcome: Primary: Expanded Disability Status Score — 2.9; 2.6 score on a scale

Study Design & Population

Study type: Interventional
Phase: N/A
Interventions: plasmapheresis (Procedure)
Age: Adult · 18+ yrs
Sex: All
Sponsor: Isfahan University of Medical Sciences
Primary completion: Jan 2012

Outcome Measures

Outcome	Result	p-value
PRIMARY Expanded Disability Status Score	2.9; 2.6	—
PRIMARY Change From Baseline in Mean Number of MS Plaques Found on Brain MRI	3.5; 7.3	—

Summary

The purpose of this study is to compare the effect of combinative induction therapy with mitoxantrone and plasmapheresis versus induction therapy with mitoxantrone alone in cases of aggressive multiple sclerosis

Eligibility Criteria

Inclusion Criteria

Aggressive multiple sclerosis in attack phase
EDSS: 1-5
No contraindication for mitoxantrone prescription
No past history of mitoxantrone injection
No history of corticosteroid and immunosuppressive therapy in last 3 months

Exclusion Criteria

Patient's incompliance
Severe drug induced side effects

View full record on ClinicalTrials.gov →

Data sourced from ClinicalTrials.gov (NCT01214317). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication.